Gyrolab Spin Blog

Apr 5, 2021 1:30:00 PM

Boost COVID-19 vaccine R&D with rapid serology tests and minimal sample and reagent consumption (Part III)

The COVID-19 pandemic has necessitated the need to 

COVID-19 vaccine R&D rapid serology tests (Part III)

generate serology data on the levels of IgM and IgG directed against the RBD of SARS-CoV-2 to help in identifying individuals with neutralizing antibodies and drive the development of therapeutics and vaccines. A number of plate-based immunoassay platforms are being employed for serology testing but there are often issues with high reagent and sample consumption, plus the limitations of laborious manual workflows and long turnaround times. Open platforms are needed that enable data to be rapidly generated using small amounts of reagent and sample, preferably over a broad analytical range to minimize the need for repeat analysis. This is now possible in an open automated platform that uses minimal amounts of precious reagent and sample. 

Read More

Topics: Vaccine


Mar 29, 2021 1:30:00 PM

Immunoassays to measure SARS-CoV-2 antibodies in serum (Part II)

Serology assays that detect antibodies to

Immunoassays for SARS-CoV-2 antibodies in serum (Part II)

 SARS-CoV-2 in human serum are critical to delivering data that provides insight into immune responses, measures health impact, and supports vaccines and therapeutics R&D. Important factors to consider are the assay targets and the best platform to ensure reliable data can be generated efficiently and with a minimum of resources, including time and reagents.

Read More

Topics: Vaccine


Mar 23, 2021 2:29:50 AM

Serology tests in COVID-19 research and vaccine development (Part I)

Serology tests in COVID-19 vaccine development (Part I)Serology tests that detect antibodies to SARS-CoV-2 in human serum are critical to gaining insight into immune responses, measuring the impact of the virus on public health, and to support the development of effective vaccines and therapeutics. This article series takes a brief snapshot of the highly dynamic situation regarding the needs for COVID-19 serology assays, how they are constructed, how they should perform, and how data can be efficiently generated using small amounts of reagents. We start with an overview.

Read More

Topics: Vaccine


Dec 9, 2020 7:17:47 PM

Capsid titer quantification for AAV-based therapeutics

AAV capsids on Gyrolab CD

 

Vectors based on AAV (adeno-associated virus) are used widely in gene therapy for in vivo gene delivery. The success of AAV-based therapeutic production depends on the availability of laboratory tools that can efficiently deliver reliable data, including the determination of virus particle titer (physical titer). To achieve this, a team at AstraZeneca searched for an immunoassay platform that could improve on ELISA in terms of dynamic range, sample volume, and productivity. Their evaluation showed that Gyrolab® system met their needs for AAV process development, with a more reliable measurement of AAV capsid titer for in-process and purified samples.

Read More

Topics: Gene therapy


Nov 12, 2020 7:19:52 PM

A new spin on ultra-high biomolecular affinity determination

It’s all about maintaining equilibrium

 

Development of high-affinity binding interactions and utilization of the appropriate tools for affinity determination are the ultimate goals of antibody therapeutic R&D. The expansion of protein engineering methods has provided powerful techniques for affinity maturation of biotherapeutics to accomplish at least part of this goal. In particular, the recent use of phage display methods for antibody affinity evolution have produced high affinity antibodies in the picomolar dissociation constant (KD) range, also with high specificity, such as the TNF-α inhibitor Humira® (AbbVie Inc.)1,2

Read More

Topics: Affinity


Jun 5, 2020 8:16:27 PM

Boosting vaccine development and production in a post-pandemic era with fast, high-performance immunoassays: Part I

Vaccine discovery and development

Vaccine discovery and development 1Vaccines have become key weapons in the fight against infectious disease and as immunotherapies for other conditions including certain cancers and Alzheimer’s disease. Immunoassays in vaccine development play a key role and meeting ever more pressing deadlines means that efficient and flexible platforms are at a premium, especially in times like these, with the COVID-19 pandemic pressing vaccine R&D to the limit. In this two-part series we will be looking at how immunoassays can contribute to vaccine R&D and production.

Read More

Topics: Immunoassay, Vaccine


Jun 5, 2020 8:11:32 PM

Boosting vaccine development and production in a post-pandemic era with fast, high-performance immunoassays: Part II

Vaccine bioprocess development and production

vaccines

Only clean drinking water can match vaccination in its ability to save millions of lives every year. In the case of the ongoing COVID-19 pandemic, the availability of a vaccine is considered a prerequisite for a return to normal life worldwide. But transforming antigens into robust vaccine products is a lengthy process. In the second article of this two-part series we will look at some examples of how immunoassays can play a key role in delivering reliable vaccine bioassay data to support efficient bioprocess development and production to ensure that vaccine production lots meet targets, time and time again.

Read More

Topics: Immunoassay, Vaccine


Apr 6, 2020 8:18:44 PM

How to think about HCP impurity testing

Getting a meaningful result

How to think about HCP impurity testing

Many good points were raised when it comes to impurity testing at the latest Gyrolab User Seminar, held in Milan in June. This included a roundtable discussion on a subject that has been a stumbling block for many – how to measure Host Cell Protein (HCP) levels in a meaningful way.

Read More

Topics: HCP, Immunogenicity, Impurity testing


Apr 6, 2020 8:18:21 PM

Enhancing the productivity of immunoassays: a 2-plex Gyrolab® assay for both preclinical and clinical studies

Target-specific reagents and immunoassay formats smoothen validation and transfer between CMC, preclinical, and clinical applications, and also to a CRO

Enhancing the productivity of immunoassays: a 2-plex Gyrolab assay for both preclinical and clinical studieRobust, accurate, precise, and time effective ligand binding assay platforms are crucial for the development of advanced bioassays for analyzing therapeutic antibody mixtures due to the inherent complexity of these drugs. This is why Symphogen A/S, Denmark chose Gyrolab system to develop assays to support chemistry, manufacturing, and controls (CMC) release and stability programs, and pharmacokinetics preclinical and clinical studies on Sym015, a novel anti-cancer biotherapeutic comprising two humanized monoclonal antibodies (mAbs).

Read More

Topics: Pharmacokinetics, Clinical trial, Preclinical studies, CRO transfer


Feb 27, 2020 4:21:35 PM

How to be confident in immunoassay determination of free versus bound target or drug

It’s all about maintaining equilibrium

It’s all about maintaining equilibriumImmunoassays must be able to generate accurate and precise quantitative measurements of analytes such as drug candidates and their targets, and many studies also demand the accurate determination of levels of free or bound drug, or target. Achieving this is a challenge and success depends on many factors, including taking steps to maintain the equilibrium formed in vivo between various molecular forms of the analyte. This can be achieved with care in sample preparation, and by using an immunoassay platform that requires minimal sample dilution, and delivers results quickly before the equilibrium can shift.

Read More